Elsevier

Vaccine

Volume 17, Issue 6, February 1999, Pages 589-596
Vaccine

Effective induction of HIV-specific CTL by multi-epitope using gene gun in a combined vaccination regime

https://doi.org/10.1016/S0264-410X(98)00238-2Get rights and content

Abstract

Reliable and effective induction of cytotoxic T-lymphocytes (CTL) is one of the prime objectives of vaccine research. Previously, novel HIV vaccine candidates were constructed as a string of CTL epitopes (20 human, 3 macaque and 1 mouse) delivered using a DNA vector [Hanke T, Schneider J, Gilbert SG, Hill AVS, McMichael A. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 1998;16:426–435.] or modified vaccinia Ankara (MVA [Hanke T, Blanchard TJ, Schneider J, Ogg GS, Tan R, Becker MSC, Gilbert SG, Hill AVS, Smith GL, McMichael A. Immunogenicities of intravenous and intramuscular administrations of MVA-based multi-CTL epitope vaccine for HIV in mice. J Gen Virol 1998;79:83–90.]), i.e. vaccine vehicles acceptable for use in humans. In mice, a single intramuscular (i.m.) needle injection of either vaccine alone elicited good CTL responses. Here, it is demonstrated that the multi-epitope DNA also induced CTL when delivered intradermally using the Accell® gene gun. The CTL responses increased after re-immunization and after three deliveries were comparable to those induced by a single i.m. injection. Recent evidence indicates that combining routes and vaccine vehicles enhances the immunogenicity of vaccine-delivered or -encoded antigens. Here, it is shown that administration of DNA by an i.m. priming/gene gun boosting more efficiently induced CTL than gene gun priming/i.m. boosting. A similar increment was obtained by sequential vaccinations using a gene gun-delivered DNA followed by recombinant MVA. Thus particular sequences of routes or vaccine vehicles rather than simple prime-boost delivery of a single vaccine is critical for an effective elicitation of CTL.

Introduction

The activity of cytotoxic T-lymphocytes (CTL) is an essential component of immune surveillance. Therefore the aim of prophylactic and therapeutic vaccines for many infectious diseases is to prime and/or expand the populations of cytotoxic effector and memory T-cells recognizing pathogen-derived epitopes. These are short usually 9-amino acid-long fragments of antigens presented to the T-cell receptor by major histocompatibility complex molecules[1]. The major obstacle to the development of such vaccines has been the difficulty in eliciting efficiently and reliably strong CTL responses.

Vaccines against acquired immunodeficiency syndrome (AIDS) will likely contain viral subunits rather than whole inactivated or attenuated human immunodeficiency virus HIV preparations as the latter approaches remain controversial for practical and safety reasons. The hopes for an effective CTL epitope-based AIDS vaccine increase with the growing evidence for a central protective role of CTL during the HIV infection2, 3, 4, 5, 6, 7, 8, 9, 10. Such a vaccine reduces the amount of protein or genetic material that needs to be delivered during vaccination, facilitates construction of combined multi-isolate vaccines, enables focusing of the immune responses towards important or conserved protein regions and reduces the chance of incorporating undesired, e.g. immunopathogenic or immunosuppressive, proteins. The polymorphism of HLA molecules causing different individuals to present different sets of peptides to T-cells can be accommodated by selecting optimal epitopes presented by the commonest HLA types. Thus, 5 epitopes are estimated to cover over 80% Caucasian and Oriental populations and 9 would cover a general population irrespective of ethnic descent[11]. If more than 1 relevant epitope for each person is required, the complexity of a broadly efficacious epitope-based vaccine will increase, but would still be feasible.

Novel HIV vaccine candidates were previously constructed. These are based on a gene coding for a string of partially overlapping epitopes recognized by CTL, designated H. This gene was delivered using plasmid pTH DNA[12]or modified virus Ankara (MVA)[13]as vaccine vehicles. Vector pTH was assembled for the purpose of DNA immunization and shown to express high levels of recombinant proteins in vitro. MVA is a strongly attenuated strain of vaccinia virus which was proven to be safe when used in over 120,000 humans[14]. The multi-CTL epitope protein H consists of 20 human (restricted by 12 different HLA alleles), 3 macaque and 1 murine epitope. Gene HM containing 1 additional murine epitope derived from Plasmodium berghei was constructed as a model multi-epitope immunogen so that a parallel induction of CTL specific for two different epitopes could be followed in mice[12]. It was shown that both a single intramuscular (i.m.) vaccination using pTH.HM DNA and a single intravenous (i.v.) or i.m. administration of MVA.HM induced consistently CTL specific for both HIV and Plasmodium epitopes12, 13. When successive prime-boost immunizations to augment the CTL induction were explored, a combined regime of i.m. DNA priming and MVA boosting was found to be the most potent protocol for the elicitation of CTL15, 16.

Gene gun-mediated immunization using the Accell® device (PowderJect Vaccines) is an alternative way of nucleic acid vaccination[17]. This approach has important advantages over the needle injection of DNA intramuscularly. It delivers DNA-coated gold particles into the dermis, a major immunological inductive site and requires 100- to 1000-fold less DNA compared to the i.m. route18, 19, 20, 21. Here, vaccination regimes employing the gene gun in a combination with i.m. DNA or MVA delivery of the multi-CTL epitope immunogen were tested in mice in the search for an efficient and reliable vaccination protocol for induction of CTL prior to commencing primate studies.

Section snippets

The pTH.HM DNA vaccine

The construction of the multi-CTL epitope vector pTH.HM was described previously[12]. The HM gene contains 36 epitopes derived from human and simian immunodeficiency virus, and Plasmodium antigens, which include 2 epitopes recognized by murine CTL. In the pTH vector, the expression of the HM gene is driven by an enhancer/immediate early promoter/intron A region derived from the human cytomegalovirus. The HM open reading frame is followed by a bovine growth hormone polyadenylation site. The

Multi-epitope DNA vaccine delivered by gene gun induced CTL

An effective induction of CTL in mice by i.m. injection of the multi-CTL epitope DNA vaccine pTH.HM was demonstrated previously[12]. However, intramuscular DNA immunization of primates is proving to be more difficult and as much as 2 mg of the vector DNA may be needed to induce detectable levels of CTL activity24, 25. In contrast, gene gun-mediated delivery induces immune responses in mice and larger animals including primates using less than 10-μg quantities of DNA17, 26, 27, 28, 29. It was

Discussion

In the course of this work, the Accell® particle delivery device- or gene gun-mediated DNA immunization using multi-epitope vectors12, 13carried out alone or in combined vaccination regimes effectively induced CTL responses. It was shown in mice that gene gun-induced CTL responses using the multi-epitope DNA vector were boostable (Fig. 1) and that 3 immunizations were required to reach levels of CTL activity comparable to those achieved by a single i.m. injection[12]. Boosted CTL were also

Acknowledgements

Grant support from MRC U.K. (A.McM., T.H., G.L.S., T.J.B.) and The Wellcome Trust (A.V.S.H.) are fully acknowledged.

References (48)

  • L.S. Klavinskis et al.

    Mucosal immunization with DNA–liposome complexes

    Vaccine

    (1997)
  • D.H. Jones et al.

    Poly(dl-lactide-co-glycolide)-encapsulated plasmid DNA elicits systemic and mucosal antibody responses to encoded protein after oral administration

    Vaccine

    (1997)
  • S. Lu et al.

    Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice

    Virology

    (1995)
  • S. Lu et al.

    Use of DNAs expressing HIV-1 particles to raise antibody responses in mice

    Virology

    (1995)
  • R.M. Zinkernagel et al.

    H-2 compatibility requirement for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus

    J Exp Med

    (1975)
  • A. Carmichael et al.

    Quantitative analysis of the human immunodeficiency virus type 1 (HIV-1)-specific cytotoxic T-lymphocyte (CTL) response at different stages of HIV-1 infection: differential CTL responses to HIV-1 and Epstein-Barr virus in late disease

    J Exp Med

    (1993)
  • P. Borrow et al.

    Virus-specific CD8+ CTL activity associated with control of viremia in primary HIV-1 infection

    J Virol

    (1994)
  • R.A. Koup et al.

    Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome

    J Virol

    (1994)
  • C. Rinaldo et al.

    High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load associated with lack of disease in HIV-1 infected long-term nonprogressors

    J Virol

    (1995)
  • S. Rowland-Jones et al.

    HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women

    Nature Med

    (1995)
  • M.R. Klein et al.

    Kinetics of gag-specific cytotoxic T-lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics

    J Exp Med

    (1995)
  • P. Borrow et al.

    Antiviral pressure exerted by HIV-1-specific cytotoxic T-lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus

    Nature Med

    (1997)
  • P.J.R. Goulder et al.

    Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS

    Nature Med

    (1997)
  • T. Hanke et al.

    Immunogenicities of intravenous and intramuscular administrations of MVA-based multi-CTL epitope vaccine for HIV in mice

    J Gen Virol

    (1998)
  • Cited by (99)

    • Immunogenicity of a lentiviral-based DNA vaccine driven by the 5'LTR of the naturally attenuated caprine arthritis encephalitis virus (CAEV) in mice and macaques

      2012, Vaccine
      Citation Excerpt :

      Despite these critical observations, there was no attempt to explore the possible use of genetic elements from other lentiviruses that are well known to be not associated with AIDS-like disease in their hosts as bases to derive HIV live-attenuated vaccines. We and others have developed non-replicating non-integrating HIV-based DNA vaccines and shown that they induce potent immune responses in rodents, but surprisingly these responses were found to be very weak in primates requiring therefore heterologous boost with proteins or viruses [15–19]. Efforts were also made to enhance the immunogenicity of these vaccines by optimizing their delivery, the expression of viral antigens or targeting particular compartment in expressing cells.

    View all citing articles on Scopus
    View full text